Ipsen Sa (IPSEY)

Trade IPSEY now with
8/3/2022 1:15:03 AM Ipsen Says Phase III RESILIENT Trial Fails To Meet Its Primary Endpoint
8/1/2022 1:49:12 AM Ipsen And Marengo Therapeutics Announce Strategic Partnership
8/1/2022 1:08:53 AM Ipsen To Advance Two Precision Immuno-Oncology Candidates From Marengo's STAR Platform Into Clinic
7/28/2022 1:18:02 AM Ipsen HY Core Net Profit Of EUR 420 Mln, Up By 19.9%. IFRS Net profit Up By 30.0% To EUR 394 Mln
6/29/2022 1:04:29 AM Ipsen Reports FDA Priority Review For Palovarotene NDA In Patients With Fibrodysplasia Ossificans Progressiva
6/27/2022 1:04:48 AM Ipsen To Buy Epizyme; Deal Anticipated To Close By End Of Q3
5/3/2022 1:07:21 AM Ipsen: EC Approves Cabometyx For Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatment
4/27/2022 1:15:20 AM Ipsen Q1 Total Sales Up 9.6% To EUR 687.9 Mln
3/25/2022 8:46:45 AM Ipsen Gets Positive CHMP Opinion For Cabometyx In Radioactive Iodine-refractory Differentiated Thyroid Cancer
3/8/2022 1:07:07 AM Ipsen: Data Show High Satisfaction Levels And Fewer Patients Reporting Injection-site Pain With Somatuline Autogel
2/15/2022 1:07:13 AM Ipsen: Cabometyx-Opdivo Show Continued Survival And Quality Of Life Benefits In Phase III Trial On Renal Cell Carcinoma